State laws mandating clinical trial reimbursement

Rated 3.94/5 based on 795 customer reviews

We assessed frequencies of themes, patterns between themes, and patterns between themes and laws.

We reviewed third-party reimbursement laws, as of September 2007, as recorded by the National Cancer Institute’s State Cancer Legislative Database.

Underrepresentation in clinical trials results in disparity in favor of participants who benefit from those trials.

From a scientific perspective, diverse representation is necessary to test for differences in outcomes and to ensure the safety of therapies across a range of biological and genetic characteristics (6).

Disparities in cancer clinical trials: an analysis of comprehensive cancer control plans. Methods We analyzed 57 CCC plans identified from Cancer PLANET (Plan, Link, Act, Network with Evidence-based Tools) and from April through December 2007.

Back to top Knowledge gained through clinical trials has been critical to preventing, diagnosing, and treating cancer.

However, not all cancer patients benefit equally from these improvements.

At a policy level, barriers may include the lack of state mandates for insurance coverage for clinical trials and the lack of appropriate enforcement and oversight of existing mandates (6).

Because barriers to and disparities in cancer clinical trial participation exist on multiple levels, addressing these issues requires a comprehensive approach.

Leave a Reply